Abstract
Aim:
To develop and optimize a sustained release multivesicular liposome (MVL) formulation of interferon (IFN) α-2b.
Methods:
IFN α-2b MVL were prepared using a typical double-emulsion procedure. The sustained release effects of IFN α-2b MVL were investigated by monitoring the blood IFN α-2b concentration using an enzyme-linked immunosorbent assay test after subcutaneous administration to healthy mice.
Results:
IFN α-2b was successfully encapsulated in MVL with high efficiency, and the integrity of encapsulated protein was maintained. After subcutaneous injection, the MVL slowly released IFN α-2b into systemic circulation in a sustained manner. The estimated serum half-life of IFN α-2b was approximately 30 h. In addition, varying the size of the MVL preparations could further modify the in vivo release profile.
Conclusion:
IFN α-2b MVL may be a useful sustained release formulation in the clinical treatment of viral diseases.
Similar content being viewed by others
Article PDF
References
Wai CT, Lok AS . Treatment of hepatitis B. J Gastroenterol 2002; 37: 771–8.
Bukowski RM, Tendler C, Cutler D, Rose E, Laughlin MM, Statkevich P . Treating cancer with PEG intron. Cancer 2002; 95: 389–96.
Glue P, Fang JW, Rouzier PR, Raffanel C, Sabo R, Gupta SK, et al. Pegylated interferon-α2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000; 68: 556–7.
Foser S, Schacher A, Weyer KA, Brugger D, Dietel E, Marti S, et al. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon α-2a (PEGASYS). Protein Expr Purif 2003; 30: 78–87.
Vanslooten ML, Boerman O, Romoren K, Kedar E, Crommelin DJ, Storm G . Liposomes as a sustained release system for human interferon-α: Biopharmaceutical aspects. Biochim Biophys Acta 2001; 1530: 134–45.
Howell SB . Clinical application of a novel sustained-release injectable drug delivery system: DepoFoamTM Technology. Cancer J 2001; 7: 219–25.
Kim S, Khatibi S, Howell SB, McCully C, Balis FM, Poplack DG . Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam. Cancer Res 1993; 53: 1596–8.
Kim S, Turker MS, Chi EY, Sela S, Martin GM . Preparation of multivesicular liposomes. Biochim Biophys Acta 1983; 728: 339–48.
Katre NV, Asherman J, Schaefer H, Hora M . Multivesicular Liposome (DepoFoam) technology for the sustained delivery of insulin-like growth factor-1 (IGF-1). J Pharm Sci 1997; 87: 1341–6.
Ye Q, Asherman J, Stevenson M, Brownson E, Katre NV . DepoFoamTM technology: a vehicle for controlled delivery of protein and peptide drugs. J Control Release 2000; 64: 155–66.
Mantripragada S . A lipid-based depot (DepoFoam technology) for sustained release drug delivery. Prog Lipid Res 2002; 41: 392–406.
Bilati U, Allemann E, Doelker E . Strategic approaches for overcoming peptide and protein instability within biodegradable nano-and microparticles. Eur J Pharm Biopharm 2005; 59: 375–88.
Ramprasad MP, Anantharamaiah GM, Garber DW, Katre NV . Sustained-delivery of an apolipoprotein E peptidomimetic using multivesicular liposomes lowers serum cholesterol levels. J Control Release 2002; 79: 207–18.
Xiao CJ, Qi XR, Maitani Y, Nagai T . Sustained release of cisplatin from multivesicular liposomes: potentiation of antitumor efficacy against S180 murine carcinoma. J Pharm Sci 2004; 93: 1718–24.
Ramprasad MP, Amini A, Kararli T, Katre NV . The sustained granulopoietic effect of progenipoietin encapsulated in multivesicular liposomes. Int J Pharm 2003; 261: 93–103.
Chamberlain MC, Khatibi S, Kim JC, Howell SB, Chatelut E, Kim S . Treatment of leptomeningeal metastasis with intraventricular administration of Depot Cytarabine (DTC101). Arch Neurol 1993; 50: 261–4.
Yaksh TL, Provencher JC, Rathbun ML, Myers RR, Powell H, Richter P, et al. Safety assessment of encapsulated morphine delivered epidurally in a sustained-release multivesicular liposome preparation in dogs. Drug Deliv 2000; 7: 27–36.
Van de Weert, M, Hennink WE, Jiskoot W . Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res 2000; 17: 1159–67.
Van Slooten ML, Visser AJWG, Van Hoek A, Storm G, Crommelin DJA, Jiskoot W . Conformational stability of human interferon-gamma on association with and dissociation from liposomes. J Pharm Sci 2000; 89: 1605–19.
Koppenhagen FJ, Visser AJWG, Herron JN, Storm G, Crommelin DJA . Interaction of recombinant interleukin-2 with liposomal bilayers. J Pharm Sci 1998; 87: 707–14.
Braun A, Alsenz J . Development and use of enzyme-linked immunosorbent assays (ELISA) for the detection of protein aggregates in interferon-alpha (IFN-α) formulations. Pharm Res 1997; 14: 1394–400.
Langston MV, Ramprasad MP, Kararli TT, Galluppi GR, Katre NV . Modulation of the sustained delivery of myelopoietin (Leridistim) encapsulated in multivesicular liposomes (DepoFoam). J Control Release 2003; 89: 87–99.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by Science and Technology Commission of Shanghai Municipality (No 024319120 and No 04DZ14902).
Rights and permissions
About this article
Cite this article
Qiu, J., Wei, Xh., Geng, F. et al. Multivesicular liposome formulations for the sustained delivery of interferon α-2b. Acta Pharmacol Sin 26, 1395–1401 (2005). https://doi.org/10.1111/j.1745-7254.2005.00188.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2005.00188.x
Keywords
This article is cited by
-
Encapsulation, pharmacokinetics and tissue distribution of interferon α-2b liposomes after intramuscular injection to rats
Archives of Pharmacal Research (2011)